Amy Iwamaye, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1255575130
Payments from drug & device makers
Across 59 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$424
- Lilly USA, LLC$159
- Insulet Corporation$146
- Mannkind Corporation$82
- Abbott$80
- Bayer$44
- plus $246 from 9 others
What the payments were for
- Food & beverage$1,11094%
- Education$121%
- Gifts$595%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $424 |
| Lilly USA, LLC | 7 | $159 |
| Insulet Corporation | 3 | $146 |
| Mannkind Corporation | 2 | $82 |
| Abbott | 5 | $80 |
| Bayer | 2 | $44 |
| BETA Bionics, Inc. | 2 | $40 |
| Tandem Diabetes Care, Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| IBSA Pharma Inc. | 1 | $24 |
| Medtronic | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Antares Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$112
How this compares
$1,181 in reported general payments places this provider in the 45th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $56,495 |
| RybelsusSemaglutide | 23 | $32,666 |
| TrulicityDulaglutide | 19 | $17,932 |
| JardianceEmpagliflozin | 11 | $17,004 |
| MounjaroTirzepatide | 12 | $12,117 |
| JanuviaSitagliptin Phosphate | 11 | $9,526 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $4,067 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $2,587 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,412 |
| SynthroidLevothyroxine Sodium | 15 | $1,002 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 11 | $809 |
| Levothyroxine Sodium | 48 | $322 |
| Repaglinide | 24 | $309 |
| Methimazole | 27 | $193 |
| Metformin Hcl | 33 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $424 | $89,16165 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $159 | $30,04931 claims |
| Boehringer IngelheimJardiance | $20 | $17,00411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Philadelphia
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Intekhab AhmedPhiladelphia$926K
- Jane MayrinPhiladelphia$628K
- Michael RickelsPhiladelphia$606K
- Steven NagelbergPhiladelphia$483K
- Kevin WilliamsPhiladelphia$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.